Clinical trials for cats

  • Description

    To investigate and identify occult coagulation disorders in cats with cholestatic liver disease before any procedures (FNA, biopsy, surgery, e-tube placement).

    Inclusion Criteria

    serum bilirubin >/= 3, ALT/ALP > 2x upper limit of reference range.

    Exclusion Criteria

    PCV < 28%, obvious neoplasia, heart disease, icterus due to sepsis or hemolysis, meds (NSAIDs, steroids, fatty acids).

    Client Benefits

    PT/PTT, plt count, pcv/ts, and TEG

    Contact Information

  • Purpose of Study”: The cancer that most commonly affects the mouth of cats is called oral squamous cell carcinoma (OSCC).  This cancer is common and responds poorly to treatment.  The average life-expectancy for cats diagnosed with this cancer is about 6 months with only 10-20% of cats alive 1 year after diagnosis.  Cats may exhibit a number of problems as a result of OSCC including a swelling in the head/throat, lack of appetite, difficulty eating or swallowing, decreased grooming behavior, excessive salivation, foul odor to breath, change in voice or difficulty in vocalizing. The purpose of this study is to determine if a drug called “Anginex” would provide a safe and effective means of treating OSCC in cats. Anginex is a peptide (small protein) that interferes with the ability of a tumor to make and maintain its blood supply, a process known as angiogenesis.  Cancer drugs that target the blood supply of a tumor are called “anti-angiogenic “or “anti-vascular” agents.  Because tumors need a blood supply to grow beyond microscopic size, inhibiting angiogenesis prevents tumors from growing and can cause tumors to shrink.  Anginex has been used in mice experimentally.  In this current study, our goals are to ensure that this agent is safe for cats and also to determine whether it has any effects on the tumor and its blood vessels and oxygen levels. Inclusion Criteria:

    1.  Cats with a diagnosis of OSCC.
    2. Cats that have not received radiation or chemotherapy (including Palladia) for treatment of the cancer.
    3. The tumor has not been surgically removed.
    4. The tumor is measurable and accessible.

    Exclusion Criteria:

    1. Cats with other systemic diseases that are uncontrolled and likely to compromise the ability of the cat to complete treatment.
    2. Tumors that are not readily accessible to biopsy and other procedures.

    Client Benefits: The study will cover the costs of certain diagnostic tests and treatment.  These include: biopsy and pathologist evaluation of tissue, blood and urine evaluation, advanced imaging with PET/MRI and CT, which can aide in future treatments of the tumor such as surgery or radiation therapy. The study will not cover the cost of the initial consultation with the oncology service. Contact Information: To make an appointment with the oncology department please call the oncology liason, Kelly Reed at 508-887-4682 For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: